Home > Insider Trading > Filing (0001012975-19-000197)

Filing Details

Accession Number:: 0001012975-19-000197
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-02-26 21:03:34
Reporting Period:: 2019-02-22

Accepted Time:: 2019-02-26 21:03:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1656328	Sienna Biopharmaceuticals Inc.	SNNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569248	Kristina Burow	8755 West Higgins Road Suite 1025 Chicago IL 60631		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-22	150,000	$2.50	2,900,575	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-02-22	150,000	$2.50	1,032,493	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-02-22	1,865,800	$2.50	1,865,800	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The shares are directly held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII and ARCH VIII LLC may therefore be deemed to beneficially own the securities held by ARCH Fund VIII. The Reporting Person has an interest in ARCH Partners VIII and ARCH VIII LLC, but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
The shares are directly held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH VIII LLC. ARCH VIII LLC may therefore be deemed to beneficially own the securities held by ARCH Fund Overage. The Reporting Person has an interest in ARCH VIII LLC, but does not have voting or investment control over the shares held by ARCH Fund Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
The shares are directly held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The Reporting Person is a managing director of AVP X LLC and may be deemed to beneficially own the shares held by ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.